CL
IBRX icon

CPWM LLC’s ImmunityBio IBRX Stock Holding History

CPWM LLC’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$117K Buy
+23,630
New +$108K 0.01% 323

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 14.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CPWM LLC's IBRX Position: Q3 2022 in Review

CPWM LLC opened a new position in ImmunityBio (IBRX) in Q3 2022: 23,630 shares worth $117K. The stake represents 0.01% of the portfolio and ranks #323 among its holdings.

126 funds tracked by Wall St. Rank hold IBRX as of Q3 2022.

  • CPWM LLC held 23,630 shares of ImmunityBio worth $117K as of Q3 2022.
  • ImmunityBio was a new CPWM LLC position in Q3 2022.
  • ImmunityBio made up 0.01% of CPWM LLC's portfolio in Q3 2022, its #323 holding.
  • 126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2022.

Based on CPWM LLC's 13F filing for Q3 2022, filed 14 Nov 2022.